All In Biotech

Investigational drug · Phase 2

DF9001

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumor, Adult.

Phase 2

Last checked: Nov 19, 2026Latest source record: Oct 29, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

1

Any phase or sponsor naming "DF9001"

First trial start

2022

Nov 15, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "DF9001", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Solid Tumor, Adult

Approved drugs for the same conditions: Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "DF9001" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Solid Tumor, Adult

  • VisugromabCTL-002, Visugromab RDEPhase 36 trials

    CatalYm GmbH · Adult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Unresectable or Metastatic Hepatocellular Carcinoma

  • anzutresgene autoleucelIMA203 Product, IMA203 product- flat dosePhase 32 trials

    Immatics US, Inc. · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult

  • CRB-701Phase 32 trials

    Corbus Pharmaceuticals Inc. · Solid Tumor, Adult, Oropharyngeal Carcinoma (OPC)

  • HMPL-453Phase 32 trials

    Hutchmed · Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult, Solid Tumor

  • VT3989Phase 32 trials

    Vivace Therapeutics, Inc · Pleural Mesothelioma, Mesothelioma, Solid Tumor, Adult

  • DabogratinibTYRA-300Phase 24 trials

    Tyra Biosciences, Inc · FGFR3 Gene Mutation, FGFR3 Gene Alteration, Achondroplasia

  • VS-7375Phase 24 trials

    Verastem, Inc. · G12D Mutated KRAS, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)

  • Tmod CAR T-cell TherapyA2B530, A2B694Phase 23 trials

    A2 Biotherapeutics Inc. · Solid Tumor, Adult, Colorectal Cancer, Colorectal Adenocarcinoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.